1. Home
  2. AVD vs SPRO Comparison

AVD vs SPRO Comparison

Compare AVD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Vanguard Corporation ($0.10 Par Value)

AVD

American Vanguard Corporation ($0.10 Par Value)

HOLD

Current Price

$2.13

Market Cap

72.4M

Sector

Industrials

ML Signal

HOLD

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVD
SPRO
Founded
1969
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.4M
71.0M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
AVD
SPRO
Price
$2.13
$1.13
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
209.7K
338.4K
Earning Date
03-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
61.11
111.81
EPS
N/A
N/A
Revenue
$515,114,000.00
$66,802,000.00
Revenue This Year
$8.82
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$2.03
$1.08
52 Week High
$5.92
$3.08

Technical Indicators

Market Signals
Indicator
AVD
SPRO
Relative Strength Index (RSI) 42.17 33.48
Support Level $2.03 $1.08
Resistance Level $2.43 $1.29
Average True Range (ATR) 0.11 0.03
MACD -0.00 0.01
Stochastic Oscillator 15.87 18.01

Price Performance

Historical Comparison
AVD
SPRO

About AVD American Vanguard Corporation ($0.10 Par Value)

American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: